Opioid treatment programs, telemedicine and COVID-19: A scoping review
- PMID: 34520702
- DOI: 10.1080/08897077.2021.1967836
Opioid treatment programs, telemedicine and COVID-19: A scoping review
Abstract
Background: Methadone and buprenorphine are effective medications for opioid use disorder (MOUD) that are highly regulated in the United States. The on-going opioid crisis, and more recently COVID-19, has prompted reconsideration of these restrictions in order to sustain and improve treatment access, with renewed interest in telemedicine. We reviewed the evidence on use of telemedicine interventions and applicability to MOUD policy changes in the post-COVID-19 treatment landscape. Methods: Ovid MEDLINE and the Cochrane Database of Systematic Reviews databases were searched from inception to April 2021 and reference lists were reviewed to identify additional studies. Studies were eligible if they examined telemedicine interventions and reported outcomes (e.g. treatment initiation, retention in care). Randomized trials and controlled observational studies were prioritized; other studies were included when stronger evidence was unavailable. One investigator abstracted key information and a second investigator verified data. We described the results qualitatively. Results: We identified nine studies: three controlled trials (two randomized), and six observational studies. Three studies evaluated patients treated with methadone and six studies with buprenorphine, including one study of pregnant women with OUD. All studies showed telemedicine approaches associated with similar outcomes (treatment retention, positive urine toxicology) compared to treatment as usual. Trials were limited by small samples sizes, lack of reporting harms, and most were conducted prior to the COVID-19 pandemic; observational studies were limited by failure to control for confounding. Conclusions: Limited evidence suggests that telemedicine may enhance access to MOUD with similar effectiveness compared with face-to-face treatment. Few studies have been published since COVID-19, and it is unclear the potential impact of these interventions on the existing racial/ethnic disparities in treatment. The COVID-19 pandemic and need for social distancing led to temporary policy changes for prescribing of MOUD that could inform additional research in this area to support comprehensive policy reforms.
Keywords: COVID-19; Telemedicine; buprenorphine; methadone; opioid use disorder.
Similar articles
-
Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?J Subst Abuse Treat. 2021 Mar;122:108196. doi: 10.1016/j.jsat.2020.108196. Epub 2020 Nov 14. J Subst Abuse Treat. 2021. PMID: 33221125 Free PMC article.
-
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.JAMA Psychiatry. 2022 Oct 1;79(10):981-992. doi: 10.1001/jamapsychiatry.2022.2284. JAMA Psychiatry. 2022. PMID: 36044198 Free PMC article.
-
Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.Subst Abus. 2022;43(1):1251-1259. doi: 10.1080/08897077.2022.2074601. Subst Abus. 2022. PMID: 35670778 Free PMC article.
-
Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review.Addict Sci Clin Pract. 2021 Nov 13;16(1):68. doi: 10.1186/s13722-021-00275-1. Addict Sci Clin Pract. 2021. PMID: 34774106 Free PMC article. Review.
-
The impact of methamphetamine/amphetamine use on receipt and outcomes of medications for opioid use disorder: a systematic review.Addict Sci Clin Pract. 2021 Oct 11;16(1):62. doi: 10.1186/s13722-021-00266-2. Addict Sci Clin Pract. 2021. PMID: 34635170 Free PMC article. Review.
Cited by
-
Patient and Clinician Experiences with the Implementation of Telemedicine and Related Adaptations in Office-Based Buprenorphine Treatment During the COVID-19 Pandemic: A Qualitative Study.Res Sq [Preprint]. 2024 Apr 22:rs.3.rs-4272282. doi: 10.21203/rs.3.rs-4272282/v1. Res Sq. 2024. PMID: 38746460 Free PMC article. Preprint.
-
Structural and social changes due to the COVID-19 pandemic and their impact on engagement in substance use disorder treatment services: a qualitative study among people with a recent history of injection drug use in Baltimore, Maryland.Harm Reduct J. 2024 May 8;21(1):91. doi: 10.1186/s12954-024-01008-8. Harm Reduct J. 2024. PMID: 38720307 Free PMC article.
-
Digital interventions targeting excessive substance use and substance use disorders: a comprehensive and systematic scoping review and bibliometric analysis.Front Psychiatry. 2024 Feb 5;15:1233888. doi: 10.3389/fpsyt.2024.1233888. eCollection 2024. Front Psychiatry. 2024. PMID: 38374977 Free PMC article. Review.
-
North Carolina Medicaid System Perspectives on Substance Use Disorder Treatment Policy Changes During the COVID-19 Pandemic.J Addict Med. 2024 Mar-Apr 01;18(2):e1-e7. doi: 10.1097/ADM.0000000000001272. Epub 2024 Feb 9. J Addict Med. 2024. PMID: 38345239
-
Barriers to retention in medications for opioid use disorder treatment in real-world practice.J Subst Use Addict Treat. 2024 May;160:209310. doi: 10.1016/j.josat.2024.209310. Epub 2024 Feb 7. J Subst Use Addict Treat. 2024. PMID: 38331319
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous